BrEPEM-LH-22017 for Older Patients With Untreated Hodgkin Lymphoma (HL)
Phase 1/2 Unknown
41 enrolled
Targeting CD19 and BCMA CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Multiple Myeloma
Phase 1/2 Unknown
24 enrolled
A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577)
Phase 1/2 Unknown
10 enrolled
Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With Refractory or Relapsed B Cell Lymphoma
Phase 1/2 Unknown
12 enrolled
CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL
Phase 1/2 Unknown
18 enrolled
Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma
Phase 1/2 Unknown
38 enrolled 12 charts
METROmaJX
Phase 1/2 Unknown
197 enrolled
Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Mantle Cell Lymphoma
Phase 1/2 Unknown
68 enrolled
Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer
Phase 1/2 Unknown
85 enrolled
MG4101 Plus Rituximab Including Lymphodepletion in Patient With r/r NHL B-cell Origin
Phase 1/2 Unknown
9 enrolled
DR-CHOP
Phase 1/2 Unknown
58 enrolled
CONFRONT
Phase 1/2 Unknown
71 enrolled
MESO-CAR T Cells Therapy for Relapsed and Refractory Epithelial Ovarian Cancer
Phase 1/2 Unknown
20 enrolled
Study of BCMA CAR-T in Multiple Myeloma
Phase 1/2 Unknown
10 enrolled
CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL.
Phase 1/2 Unknown
20 enrolled
NRT-01
Phase 1/2 Unknown
40 enrolled
CD19 CART Cells for Patients With Relapse and Refractory CD19+ B-cell Lymphoma.
Phase 1/2 Unknown
20 enrolled
PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies
Phase 1/2 Unknown
20 enrolled
Anti-GPC3 CAR-T for Treating GPC3-positive Advanced Hepatocellular Carcinoma (HCC)
Phase 1/2 Unknown
20 enrolled
MatchCART
Phase 1/2 Unknown
20 enrolled
Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes
Phase 1/2 Unknown
18 enrolled
Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver Cancer
Phase 1/2 Unknown
50 enrolled
Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer
Phase 1/2 Unknown
30 enrolled
Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Women With Metastatic Breast Cancer
Phase 1/2 Unknown
50 enrolled
Biological Therapy in Treating Women With Metastatic Breast Cancer
Phase 1/2 Unknown
60 enrolled
Monoclonal Antibody Plus Cyclophosphamide in Treating Patients With Metastatic Cancer
Phase 1/2 Unknown
Combination Chemotherapy Plus Filgrastim in Treating Patients With HIV-Related Non-Hodgkin's Lymphoma
Phase 1/2 Unknown
30 enrolled
Alemtuzumab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV T-Cell Non-Hodgkin's Lymphoma
Phase 1/2 Unknown
84 enrolled
Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's Lymphoma
Phase 1/2 Unknown
12 enrolled
HLA-haploidentical Hematopoietic Stem Cell Transplantation for Children and Adolescents With Acute Leukemia, Myelodysplastic Syndrome and Solid Tumors
Phase 1/2 Unknown
10 enrolled
Combination of Bortezomib, Fludarabine and Cyclophosphamide Treat Recurrent Mantle Cell Lymphoma
Phase 1/2 Unknown
40 enrolled
Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors
Phase 1/2 Unknown
12 enrolled
Zevalin With Non Myeloablative Allogeneic Stem Cell Transplantation in Patients With Non Hodgkin Lymphoma
Phase 1/2 Unknown
20 enrolled